title: [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
abstract: A 44-year-old female with refractory acute myelogeneous leukemia had experienced an early relapse after a third complete remission (CR) with combination chemotherapy (BHAC-AMP) using daily one-shot infusion of 20 mg aclarubicin (ACR). Further treatments including intermediate dose of cytosine arabinoside (Ara-C) were not effective. After treatment with a continuous administration of low dose ACR (9 mg/day) and Ara-C (21 mg/day) for 14 days she entered a fourth CR. The mechanism of this treatment relates to both cell-killing and differentiation effects on leukemic cells.
authors.affiliation: Fourth Department of Internal Medicine, Tokai University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Kawada
authors.forename: M
authors.initials: M
authors.lastname: Komatsuda
authors.forename: A
authors.initials: A
authors.lastname: Masumoto
authors.forename: R
authors.initials: R
authors.lastname: Fukuda
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Yonekura
authors.forename: Y
authors.initials: Y
authors.lastname: Ichikawa
authors.forename: T
authors.initials: T
authors.lastname: Nagao
authors.forename: S
authors.initials: S
authors.lastname: Arimori
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*
chemical_list: D003561:Cytarabine; D015250:Aclarubicin